SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

India Globalization Capital, Inc. – ‘10-Q’ for 12/31/20 – ‘EX-32.1’

On:  Friday, 2/12/21, at 5:58pm ET   ·   As of:  2/16/21   ·   For:  12/31/20   ·   Accession #:  1185185-21-201   ·   File #:  1-32830

Previous ‘10-Q’:  ‘10-Q’ on 11/20/20 for 9/30/20   ·   Next:  ‘10-Q’ on 8/11/21 for 6/30/21   ·   Latest:  ‘10-Q’ on 2/14/24 for 12/31/23   ·   1 Reference:  To:  IGC Pharma, Inc. – ‘POS AM’ on 1/22/21

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/16/21  India Globalization Capital, Inc. 10-Q       12/31/20   84:5.2M                                   Federal Filings, LLC/FA

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    498K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
11: R1          Document And Entity Information                     HTML     51K 
12: R2          Condensed Consolidated Balance Sheets               HTML    116K 
13: R3          Condensed Consolidated Balance Sheets               HTML     40K 
                (Parentheticals)                                                 
14: R4          Condensed Consolidated Statements of Operations     HTML     75K 
                and Comprehensive Loss                                           
15: R5          Condensed Consolidated Statement of Stockholders?   HTML     71K 
                Equity                                                           
16: R6          Condensed Consolidated Statements of Cash Flows     HTML     95K 
17: R7          Business Description                                HTML     31K 
18: R8          Summary of Significant Accounting Policies          HTML     74K 
19: R9          Inventory                                           HTML     36K 
20: R10         Deposits and Advances                               HTML     38K 
21: R11         Intangible Assets                                   HTML     54K 
22: R12         Property, Plant and Equipment, Net                  HTML     54K 
23: R13         Investments in Non-Marketable Securities            HTML     34K 
24: R14         Claims and Advances                                 HTML     36K 
25: R15         Leases                                              HTML     61K 
26: R16         Accrued and Other Liabilities                       HTML     35K 
27: R17         Loans and Other Liabilities                         HTML     29K 
28: R18         Commitments and Contingencies                       HTML     27K 
29: R19         Securities                                          HTML     27K 
30: R20         Stock-Based Compensation                            HTML     66K 
31: R21         Fair Value of Financial Instruments                 HTML     83K 
32: R22         Segment Information                                 HTML    119K 
33: R23         Subsequent Events                                   HTML     26K 
34: R24         Accounting Policies, by Policy (Policies)           HTML    113K 
35: R25         Summary of Significant Accounting Policies          HTML     41K 
                (Tables)                                                         
36: R26         Inventory (Tables)                                  HTML     35K 
37: R27         Deposits and Advances (Tables)                      HTML     38K 
38: R28         Intangible Assets (Tables)                          HTML     56K 
39: R29         Property, Plant and Equipment, Net (Tables)         HTML     54K 
40: R30         Investments in Non-Marketable Securities (Tables)   HTML     34K 
41: R31         Claims and Advances (Tables)                        HTML     36K 
42: R32         Leases (Tables)                                     HTML     66K 
43: R33         Accrued and Other Liabilities (Tables)              HTML     35K 
44: R34         Stock-Based Compensation (Tables)                   HTML     69K 
45: R35         Fair Value of Financial Instruments (Tables)        HTML     81K 
46: R36         Segment Information (Tables)                        HTML    118K 
47: R37         Business Description (Details)                      HTML     26K 
48: R38         Summary of Significant Accounting Policies          HTML     33K 
                (Details)                                                        
49: R39         Summary of Significant Accounting Policies          HTML     42K 
                (Details) - Disaggregation of Revenue                            
50: R40         Inventory (Details)                                 HTML     27K 
51: R41         Inventory (Details) - Schedule of Inventory,        HTML     31K 
                Current                                                          
52: R42         DEPOSITS AND ADVANCES (Details) - Deferred Costs,   HTML     35K 
                Capitalized, Prepaid, and Other Assets Disclosure                
53: R43         Intangible Assets (Details)                         HTML     33K 
54: R44         Intangible Assets (Details) - Schedule of           HTML     46K 
                Intangible Assets And Goodwill                                   
55: R45         Intangible Assets (Details) - Schedule of           HTML     34K 
                Finite-Lived Intangible Assets, Future                           
                Amortization Expense                                             
56: R46         Property, Plant and Equipment, Net (Details)        HTML     25K 
57: R47         Property, Plant and Equipment, Net (Details) -      HTML     59K 
                Property, Plant and Equipment                                    
58: R48         Investments in Non-Marketable Securities (Details)  HTML     24K 
59: R49         Investments in Non-Marketable Securities (Details)  HTML     30K 
                - Schedule of Investments                                        
60: R50         Claims and Advances (Details)                       HTML     27K 
61: R51         Claims and Advances (Details) - Schedule of Other   HTML     32K 
                Assets, Noncurrent                                               
62: R52         Leases (Details)                                    HTML     32K 
63: R53         Leases (Details) - Lease, Cost                      HTML     32K 
64: R54         Leases (Details) - Lessee, Operating Lease,         HTML     39K 
                Disclosure                                                       
65: R55         Leases (Details) - Lessee, Operating Lease,         HTML     40K 
                Liability, Maturity                                              
66: R56         Accrued and Other Liabilities (Details)             HTML     27K 
67: R57         Accrued and Other Liabilities (Details) - Schedule  HTML     33K 
                of Accounts Payable and Accrued Liabilities                      
68: R58         Loans and Other Liabilities (Details)               HTML     54K 
69: R59         Commitments and Contingencies (Details)             HTML     26K 
70: R60         Securities (Details)                                HTML     50K 
71: R61         Stock-Based Compensation (Details)                  HTML     52K 
72: R62         Stock-Based Compensation (Details) - Schedule of    HTML     35K 
                Share-based Payment Award, Stock Options,                        
                Valuation Assumptions                                            
73: R63         Stock-Based Compensation (Details) - Nonvested      HTML     42K 
                Restricted Stock Shares Activity                                 
74: R64         Stock-Based Compensation (Details) - Share-based    HTML     51K 
                Payment Arrangement, Option, Activity                            
75: R65         Fair Value of Financial Instruments (Details)       HTML     28K 
76: R66         Fair Value of Financial Instruments (Details) -     HTML     48K 
                Schedule of Fair Value, Assets and Liabilities                   
                Measured on Recurring Basis                                      
77: R67         Segment Information (Details)                       HTML     27K 
78: R68         Segment Information (Details) - Revenue from        HTML     36K 
                External Customers by Products and Services                      
79: R69         Segment Information (Details) - Revenue from        HTML     40K 
                External Customers by Geographic Areas                           
80: R70         Segment Information (Details) - Schedule of         HTML     48K 
                Revenue from External Customers and Long-Lived                   
                Assets, by Geographical Areas                                    
81: R71         Subsequent Events (Details)                         HTML     28K 
83: XML         IDEA XML File -- Filing Summary                      XML    158K 
82: EXCEL       IDEA Workbook of Financial Reports                  XLSX     97K 
 5: EX-101.INS  XBRL Instance -- igc-20201231                        XML   1.27M 
 7: EX-101.CAL  XBRL Calculations -- igc-20201231_cal                XML    132K 
 8: EX-101.DEF  XBRL Definitions -- igc-20201231_def                 XML    608K 
 9: EX-101.LAB  XBRL Labels -- igc-20201231_lab                      XML   1.09M 
10: EX-101.PRE  XBRL Presentations -- igc-20201231_pre               XML    606K 
 6: EX-101.SCH  XBRL Schema -- igc-20201231                          XSD    164K 
84: ZIP         XBRL Zipped Folder -- 0001185185-21-000201-xbrl      Zip    153K 


‘EX-32.1’   —   Certification — §906 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:  <>  <> 

Exhibit 32.1

 

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ram Mukunda, certify, as of the date hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of India Globalization Capital, Inc. on Form 10-Q for the period ended December 31, 2020, (i) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) that information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of India Globalization Capital, Inc. at the dates and for the periods indicated. 

 

 

Date: February 12, 2021

By:

/s/ Ram Mukunda                

 

 

Ram Mukunda

 

 

Chief Executive Officer and President

(Principal Executive Officer)

 

 

I, Claudia Grimaldi, certify, as of the date hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of India Globalization Capital, Inc. on Form 10-Q for the period ended December 31, 2020, (i) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) that information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of India Globalization Capital, Inc. at the dates and for the periods indicated. 

 

 

Date: February 12, 2021

By:

/s/ Claudia Grimaldi

 

 

Claudia Grimaldi

 

 

Vice President

(Principal Financial Officer)

 

 

 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed as of:2/16/21
Filed on:2/12/21
For Period end:12/31/20CORRESP,  UPLOAD
 List all Filings 


1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/22/21  IGC Pharma, Inc.                  POS AM                 4:206K                                   Federal Filings, LLC/FA
Top
Filing Submission 0001185185-21-000201   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 4, 3:55:39.2pm ET